Diagnostic Performance of Three ELISAs for Detection of Antibodies against SARS-CoV-2 in Human Samples. (16th August 2022)

• Record Type: Journal Article
• Authors: Meira, Cássio; Silva, Dahara; Santos, Ivanilson; Barreto, Breno; Rocha, Vinícius; Santos, Emanuelle; dos Reis, Bruna; Evangelista, Afrânio; Ribeiro dos Santos, Ricardo; Machado, Bruna; Ribeiro, Guilherme; Badaró, Roberto; Soares, Milena
• Other Names: Del Hierro Isabel Academic Editor.
• Is Part Of: TheScientificWorldjournal. Volume 2022(2022)
• Publication Date: 2022-08-16
• Subjects: Science -- Periodicals; Technology -- Periodicals; Medicine -- Periodicals; 505
• DOI: 10.1155/2022/7754329
• Languages: English
• ISSNs: 2356-6140

Abstract

Abstract : Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19) is a disease with a high rate of transmission. Serological tests are important to perform surveys and to determine the immunological status of the population. Based on this, we evaluated three enzyme-linked immunoassays (ELISAs) using different antigens from SARS-CoV-2 in a cohort of 161 patients. The performance of the ELISA developed for immunoglobulin G (IgG) measurement against SARS-CoV-2 was evaluated based on sensitivity, specificity, and accuracy. We found specificities of 0.98, 0.98, and 0.99 and sensitivities of 0.99, 0.91, and 0.87 for the nucleocapsid (N) protein, spike protein, and receptor binding domain (RBD) fraction, respectively. The accuracy assessment indicated the N protein (accuracy = 0.98) as the antigen most likely to give a correct diagnosis. Overall, the antibody responses were present for all three proteins in subjects with confirmed SARS-CoV-2 infections, showing a similar pattern of antibody production for different antigens. In summary, these highly sensitive and specific ELISAs, with a more competitive price, appear to be a valid approach for the serodiagnosis of COVID-19.